Table 1.
Baseline patient characteristics (regorafenib, n=32)
| Characteristic | No. (%) |
|---|---|
| Median age (range, yr) | 57 (29-79) |
| Gender | |
| Male | 20 (62.5) |
| Female | 12 (37.5) |
| ECOG performance status | |
| 0-1 | 31 (96.9) |
| 2 | 1 (3.1) |
| Primary site of disease | |
| Colon | 21 (65.6) |
| Rectum | 11 (34.4) |
| Disease status | |
| Recurrent | 15 (46.9) |
| Metastatic | 17 (53.1) |
| KRAS mutation | |
| No | 18 (56.3) |
| Yes | 11 (34.4) |
| Unknown | 3 (9.4) |
| No. of previous systemic anticancer therapiesa) | |
| 1-3 | 20 (62.5) |
| ≥ 4 | 12 (37.5) |
| Previous anti-VEGF treatment (bevacizumab) | 18 (56.3) |
| Previous anti-EGFR treatment (cetuximab) | 13 (40.6) |
| Time from diagnosis of metastasis (mo) | |
| < 25 | 8 (25.0) |
| ≥ 25 | 24 (75.0) |
ECOG, Eastern Cooperative Oncology Group; VEGF, vascular endothelial growth factor; EGFR, epidermal growth factor receptor.
a)
On or after diagnosis of metastatic disease.